Photobiomodulation in the management of oral disease: dose, mechanisms and practical considerations

Photobiomodulation (PBM) uses non-ionizing light, mainly red and near-infrared, at non-thermal doses to modulate inflammation and promote tissue repair. This review assesses the evidence for PBM in oral disease using an evidence hierarchy. Prevention of oral mucositis (OM), its strongest indication, has reached guideline-level recommendation and should be available for patients receiving head and neck radiotherapy with or without chemotherapy, or high-dose chemotherapy with stem cell transplantation. For pain after third molar surgery and endodontic treatment, meta-analyses show only short-term benefits with low certainty of evidence. The BMJ clinical guideline regarding pain management of temporomandibular disorders (TMD) issued a conditional recommendation against PBM. Similarly, the European Federation of Periodontology (EFP) and the American Dental Association (ADA) have not found clinical benefits and both guidelines recommend against adjunctive laser therapy. In orthodontics, Cochrane reviews found low to very low certainty evidence for either pain reduction or shortening of treatment time. Evidence for implant osseointegration, nerve recovery, burning mouth syndrome, and other mucosal conditions remains limited to small trials. Methodology varied across indications: missing dosimetry information prevents replication of trials, and lack of verified patient blinding is a concern. With eyewear protection, PBM's safety profile is high; its use over oncological areas, however, still lacks clinical evidence. For other indications, evidence does not support routine use, and PBM should be used with patient consent and explanation of unproven benefit. Complete documentation of treatment parameters is recommended, and regulatory clearance of a device should not be interpreted as evidence of clinical efficacy.

Authors

Institutions

Publication Details

Journal
Frontiers in Oral Health
Published
2026-11-16
DOI
https://doi.org/10.3389/froh.2026.2015491
Primary Topic
Laser Applications in Dentistry and Medicine
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Photobiomodulation in the management of oral disease: dose, mechanisms and practical considerations

Manoela Martins, Gal Hiltch, Liviu Steier, Jose Antonio Poli de Figueiredo
3 links
Frontiers in Oral Health
Laser Applications in Dentistry and Medicine
article

Photobiomodulation in the management of oral disease: dose, mechanisms and practical considerations

Manoela Martins, Gal Hiltch, Liviu Steier, Jose Antonio Poli de Figueiredo
article en

Abstract

Photobiomodulation (PBM) uses non-ionizing light, mainly red and near-infrared, at non-thermal doses to modulate inflammation and promote tissue repair. This review assesses the evidence for PBM in oral disease using an evidence hierarchy. Prevention of oral mucositis (OM), its strongest indication, has reached guideline-level recommendation and should be available for patients receiving head and neck radiotherapy with or without chemotherapy, or high-dose chemotherapy with stem cell transplantation. For pain after third molar surgery and endodontic treatment, meta-analyses show only short-term benefits with low certainty of evidence. The BMJ clinical guideline regarding pain management of temporomandibular disorders (TMD) issued a conditional recommendation against PBM. Similarly, the European Federation of Periodontology (EFP) and the American Dental Association (ADA) have not found clinical benefits and both guidelines recommend against adjunctive laser therapy. In orthodontics, Cochrane reviews found low to very low certainty evidence for either pain reduction or shortening of treatment time. Evidence for implant osseointegration, nerve recovery, burning mouth syndrome, and other mucosal conditions remains limited to small trials. Methodology varied across indications: missing dosimetry information prevents replication of trials, and lack of verified patient blinding is a concern. With eyewear protection, PBM's safety profile is high; its use over oncological areas, however, still lacks clinical evidence. For other indications, evidence does not support routine use, and PBM should be used with patient consent and explanation of unproven benefit. Complete documentation of treatment parameters is recommended, and regulatory clearance of a device should not be interpreted as evidence of clinical efficacy.

Frontiers in Oral HealthVol. 7
Universidade Federal do Rio Grande do Sul (BR), University of Pennsylvania (US)
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Conselho Nacional de Desenvolvimento Científico e Tecnológico
Good health and well-being
Laser Applications in Dentistry and Medicine
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon